Codiya Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 2.50 M
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2024
- Revenue Growth 46.68%
- Profit Growth 60.02%
- Ebitda -39.08%
- Net Worth 6.09%
- Total Assets -9.31%
About Codiya Pharma
Codiya Pharma Limited (CPL) is a Public Limited Indian Non-Government Company incorporated in India on 03 November 2016 (Eight years and three months 6 days old ). Its registered office is in Bangaluru, Karnataka, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 2.50 M, as per Ministry of Corporate Affairs (MCA) records.
Nischal Jain, Amit Jain, Sudha, and Four other members serve as directors at the Company.
Company Details
-
Location
Bangaluru, Karnataka, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U74999KA2016PLC097581
-
Company No.
097581
-
Company Classification
Public Limited Indian Non-Government Company
-
Incorporation Date
03 Nov 2016
-
Date of AGM
30 Sep 2024
-
Date of Balance Sheet
31 Mar 2024
-
Listing Status
Unlisted
-
ROC Code
Roc Bangalore
Industry
Who are the key members and board of directors at Codiya Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Nischal Jain
|
Managing Director | 03-Nov-2016 | Current |
Board Members (6)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
|
Shivang Jain
|
Director | 03-Nov-2016 | Current |
|
Amit Jain
|
Director | 03-Nov-2016 | Current |
|
Sudha
|
Director | 03-Nov-2016 | Current |
|
Ashish Jain
|
Director | 03-Nov-2016 | Current |
|
Savita Jain
|
Director | 03-Nov-2016 | Current |
|
Nidhi Jain
|
Director | 03-Nov-2016 | Current |
Financial Performance of Codiya Pharma.
Codiya Pharma Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 46.68% increase. The company also saw a substantial improvement in profitability, with a 60.02% increase in profit. The company's net worth moved up by a moderate rise of 6.09%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Codiya Pharma?
In 2018, Codiya Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Nexure Lifesciences Private LimitedNischal Jain, Sudha and 1 more are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Codiya Pharma?
Unlock and access historical data on people associated with Codiya Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Codiya Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Codiya Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.